Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX‐02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.647
Abstract: ELX‐02 is an investigational synthetic eukaryotic ribosome–selective glycoside optimized as a translational read‐through molecule that induces read through of nonsense mutations, resulting in normally localized full‐length functional proteins. ELX‐02 is being developed as a therapy… read more here.
Keywords: caused nonsense; safety; increase; single ascending ... See more keywords
Safety, Tolerability and Pharmacokinetics of Single Ascending and Multiple Oral Doses of Tegoprazan in Healthy Chinese Subjects
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Drug Investigation"
DOI: 10.1007/s40261-020-00986-4
Abstract: Background and Objectives Tegoprazan is one of the potassium-competitive acid blockers (P-CABs). It exhibits its anti-secretory effects by competitively and reversibly blocking the availability of K + of the H + , K + -ATPase.… read more here.
Keywords: healthy chinese; administration; safety; single ascending ... See more keywords
Intranasal dexmedetomidine in elderly subjects with or without beta blockade: a randomised double-blind single-ascending-dose cohort study.
Sign Up to like & getrecommendations! Published in 2020 at "British journal of anaesthesia"
DOI: 10.1016/j.bja.2019.12.025
Abstract: BACKGROUND The aim of this double-blind, placebo-controlled, single-ascending-dose study was to determine the safety and tolerability of intranasal dexmedetomidine in the elderly. METHODS We randomly assigned 48 surgical patients ≥65 yr of age to receive… read more here.
Keywords: double blind; intranasal dexmedetomidine; dexmedetomidine elderly; single ascending ... See more keywords
Phase I Single Ascending Dose and Food Effect Study in Healthy Adults and Phase I/IIa Multiple Ascending Dose Study in Patients with Pulmonary Tuberculosis to Assess Pharmacokinetics, Bactericidal Activity, Tolerability, and Safety of OPC-167832
Sign Up to like & getrecommendations! Published in 2023 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01477-22
Abstract: OPC-167832, an inhibitor of decaprenylphosphoryl-β-d-ribose 2’-oxidase, demonstrated potent antituberculosis activity and a favorable safety profile in preclinical studies. This report describes the first two clinical studies of OPC-167832: (i) a phase I single ascending dose… read more here.
Keywords: single ascending; opc 167832; ascending dose; activity ... See more keywords